Eisai poaches senior Pfizer and Sanofi execs for neurology group
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim
Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …
Perrigo name new head of its combined UK and Ireland business
April 26, 2016Sales and Marketing Ireland, Perrigo, UK, lister, neil, new head
Perrigo has named Neil Lister as the head of its newly-combined UK and Ireland business. The manufacturer and distributor of …
Northern Powerhouse life sciences contributing £10 billion to UK economy, says minister
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Northern Powerhouse, contribution, economy, exporting, george freeman, investment, life sciences, minister, north
Minister for Life Sciences, George Freeman MP, has revealed that life sciences businesses within the Northern Powerhouse are contributing over …
US panel says Sarepta’s trial DMD drug not proven effective
April 26, 2016Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta
A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …
Bayer’s earnings beat estimates as blockbusters shine
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales
Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
AstraZeneca’s COPD therapy gets US FDA approval
April 26, 2016Research and Development, Sales and Marketing AstraZeneca, COPD, US FDA, drug approval
UK drug firm AstraZeneca (LSE: AZN) said the US Food and Drug Administration has approved its therapy to treat chronic …
Allergan breaks ground on $200 million expansion at Texas site
April 26, 2016Manufacturing and Production Allergan, doubling, expansion, eye care, facility, investment, manufacturing, size, texas, waco
Allergan (NYSE: AGN) has broken ground on a $200 million expansion at its manufacturing facility in Waco, Texas. The expansion …
Novartis exploring almost $14-billion stake sale in Roche – reports
April 26, 2016Manufacturing and Production, Sales and Marketing Financial, Merger & Acquisition, Novartis, Roche, Stake sale
Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: …
EU grants approval for Gilead’s HIV treatment Descovy
April 26, 2016Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf
Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …
Valeant names Joseph Papa as new chief executive officer
April 25, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson
Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …
FDA, WHO criticise integrity of data at contract research firm Semler
April 25, 2016Research and Development, Sales and Marketing FDA, India, WHO, World Health Organisation, semler, semler research
The US Food and Drug Administration and the World Health Organisation have raised serious concerns related to violations of good …
Weekly Movers: PTC Therapeutics, Celator Pharmaceuticals, Chiasma, Sarepta and more…
April 25, 2016Research and Development, Sales and Marketing
With the earnings season in full swing this week investors focussed on the impact on stock moves as companies declared …
Pfizer, GSK’s anti-smoking drugs not linked to increase in serious neuropsychiatric adverse events – Study
April 25, 2016Research and Development, Sales and Marketing
Pharma giant Pfizer’s (NYSE: PFE) smoking cessation drug Chantix (varenicline) did not show an increase in serious neuropsychiatric adverse events …
Valeant receives further default notices due to its delayed 10-K filing
April 25, 2016Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry
Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …
Merck’s colorectal cancer drug meets primary endpoint in Phase III study
April 25, 2016Research and Development, Sales and Marketing Erbitux, Merck, Serono, cancer drugs, colorectal cancer, increased survival, oncology, phase 3, phase III
Merck (FWB: MRK) has announced that its Phase III clinical trial of Erbitux, in combination with Folfox, met its primary …
AstraZeneca to sequence genomes to develop new drugs
April 22, 2016Medical Communications, Sales and Marketing AstraZeneca, Finland, Wellcome Trust, collaboration, genome, genomics, human longevity, institute for molecular medicine, sanger institute
AstraZeneca (LSE: AZN) has announced an integrated genomics initiative that aims to transform the drug discovery and development across is …
AbbVie announces further industry and academic collaborations
April 22, 2016Medical Communications, Research and Development AbbVie, collaboration, commercialisation, cytomx, partnership, research, university of chicago
AbbVie (NYSE: ABBV) has announced further collaborations that will see it partner with industry and academia to develop oncology candidates …
Biogen Q1 profits rise boosted by Tecfidera sales
April 22, 2016Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera
Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter …
Novartis muscular drug fails in Phase III trials
April 22, 2016Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III
A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
Actelion ups outlook for 2016, reports Q1 net income up 12%
April 22, 2016Medical Communications, Sales and Marketing Actelion, Biotechnology, Q1 results, earnings, outlook
Swiss biotech company Actelion (VTX: ATLN) raised its outlook for 2016 and reported a 12% rise in first quarter net …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
